Recent Company News

• 08:39 PM ET Oct 23, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 07:10 PM ET Nov 05, 2025
  

  Immuron proposes placement of 8.5M shares at A$0.0756/sh via US ATM facility - Appendix 3B (A$0.07, -0.02)

• 11:11 PM ET Nov 04, 2025
  

  FDA approves IND application for Immuron's IMM-529 (A$0.07, 0.00)

• 07:57 PM ET Nov 04, 2025
  

  StreetAccount Summary - Australia unusual volume traders

• 06:33 PM ET Oct 30, 2025
  

  Immuron's IND for IMM-529 under active review by FDA; FDA has issued request for additional clinical information (A$0.09, 0.00)

• 06:36 PM ET Oct 23, 2025
  

  Immuron launches PROIBS for Irritable Bowel Syndrome into Australian market (A$0.08, 0.00)

• 04:42 PM ET Oct 22, 2025
  

  Transcript Intelligence: Immuron at Emerging Growth Conference (A$0.08, 0.00)

• 11:08 AM ET Oct 17, 2025
  

  Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target